Comparison of Clomiphene Citrate and Gonadotropins in Ovulation Induction Cycles
- Registration Number
- NCT00835744
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Brief Summary
The purpose of the present study is to analyse prospectively if highly purified hMG compared with increased dose of clomiphene citrate has different outcomes in folliculogenesis in ovulation induction cycles.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
- < 39 years old on day of randomisation
- FSH < 12 (in the early follicular phase)
- Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation.
- Chronic oligo or anovulation (WHO 2)
- BMI between 18 and 31 (both inclusive)
Exclusion Criteria
- ≥ 39 years old on day of randomisation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description B gonadotropins Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, gonadotropins (75IU) are administered from day 13 until day 17 of the cycle. A clomiphene citrate Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, an increased dose of 100 mg of clomiphene citrate is administered from day 13 until day 17 of the cycle.
- Primary Outcome Measures
Name Time Method folliculogenesis april 2009
- Secondary Outcome Measures
Name Time Method pregnancy rate april 2009
Trial Locations
- Locations (1)
UZ Brussel
🇧🇪Jette, Belgium